Community-acquired Pneumonia Due to Chlamydia Pneumoniae
ConditionCommunity-Acquired Pneumonia
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorCentre Hospitalier de Saint-Denis
About this trial
This international retrospective Franco-Swiss study focuses on community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae.
The working hypothesis is that the prevalence of C. pneumoniae pneumonia is overestimated by the medical community.
The primary objective is to determine the true prevalence of C. pneumoniae infections among patients with pneumonia who underwent simplex or multiplex PCR testing.
Secondary objectives include;
1. Outpatient management 2. Hospitalization in a medical ward 3. Admission to the intensive care unit 4. In-hospital mortality 5. Radiological presentation of patients with community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae 6. Prevalence of viral or bacterial co-infections associated with C. pneumoniae CAP
Eligibility criteria
Qualifiers
Positive simplex or multiplex PCR for Chlamydia pneumoniae on an upper or lower respiratory tract specimen between January 2015 and December 2025.
Availability of clinical data allowing confirmation of pneumonia diagnosis.
Disqualifiers
Patient opposition to the use of medical data for research purposes.
Absence of pneumonia diagnosis.
Insufficient clinical data for analysis.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov